In a trial, a lung cancer drug combo extended median survival by nearly five months.
AstraZeneca and HUTCHMED reported that a combination of TAGRISSO and savolitinib extended median overall survival by nearly five months in a Phase III trial for EGFR-mutated non-small cell lung cancer. The trial showed a 32% reduction in the risk of death. Results were presented at the ESMO Congress 2026. The companies submitted an NDA to the FDA for this treatment. TAGRISSO is AstraZeneca's drug, while savolitinib is jointly developed by both companies.
How this was made
The 30-second read
Why it matters
The data show a 5‑month median overall‑survival improvement and a hazard ratio of 0.68, indicating a meaningful clinical benefit.
Market read
First‑time release of pivotal trial data that could expand AstraZeneca's oncology portfolio and drive near‑term stock movement.
What to watch
Potential competition from other MET inhibitors and the need for FDA approval could delay revenue.
Background
The SAFFRON Phase III trial data were presented at the ESMO 2026 Congress, marking the first public disclosure of the results.
Ticker impact
AstraZeneca co‑developed the TAGRISSO plus savolitinib regimen and announced Phase III SAFFRON trial results showing a five‑month overall‑survival gain.
upward pressure as investors price in potential revenue from the new indication.
First‑time disclosure of statistically significant survival benefit; market typically rewards breakthrough oncology data.
Market effects
May boost the broader EGFR‑mutated NSCLC therapeutic space and increase interest in MET‑targeted combos.
Positive for European biotech and pharma stocks, especially those with oncology pipelines.
Global relevance as the drug could be launched worldwide pending FDA approval.
Counterpoint
If regulatory hurdles or safety concerns emerge, the upside could be limited.
Key entities
- CompanyAstraZeneca
Co‑developer and commercial partner for the TAGRISSO plus savolitinib regimen.
- CompanyHUTCHMED
Co‑developer of savolitinib.
